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A B S T R A C T
Post-traumatic Stress Disorder (PTSD) frequently occurs in commorbidity with different mental disorders, including
suicidal behaviour. Group of biological factors, including serotonergic system, HPA axis and some genetic factors, are be-
ing studied as potential markers, able to differentiate suicidal and non-suicidal behaviour across the group of PTSD pa-
tients. This study is examining statistical relation between platelet serotonine concentration and serum cortisole concen-
tration, within the group of PTSD patients with and without attempted suicide, treated at »Sveti Ivan« Psychiatric
Hospital in Zagreb. The hypothesis of this study is that periferal biochemical markers are different accross the groups of
PTSD patients with and without attempted suicide and the group of healthy controls. Our results have shown signifi-
cantly lower platelet serotonine concentration in PTSD patients with and without suicide behaviour, compared to healthy
controls. There are no statisticaly significant differences of the serum cortisole concentration accross observed groups.
Our results correspond with those reported by other authors in this area of research, suggesting that platelet serotonine
level might be used as potential periferal marker to detect risk of suicidal behaviour in PTSD patients.
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Introduction
Post-traumatic stress disorder (PTSD), even fifteen
years upon the Croatian War of Independence, still pre-
sents significant public health, diagnostic and therapeu-
tical challange, as well as the social problem. PTSD often
appears in comorbidity with various psychiatric disor-
ders, and is know to be associated with suicidal behaviour.
The involvement of the serotonergic system, hypotala-
mic-pituitary-adrenal axis (HPA axis), as well as genetic
factors, within the group of biological factors, is being
reserched for their potential marker role in the process
of distinguishing psychiatric patients with and without
suicidal behaviour. Biological factors of suicidal behaviour
are present in number of psychiatric disorders, while be-
ing very specific for some psychiatric disorders, which
leads to the research hypothesis about distinction of bio-
logical and/or biochemical behavioural factors in the
group of PTSD patients with and without attempted
suicide1.
Both the increased understanding of relationship
among the platelet serotonine concentration changes
and blood cortisol level changes, in PTSD patients with
and without suicidal behaviour, with application of the
timely and efficient suicide prevention measures and
procedure, might contribute to the increased overall efi-
cacy of suicide prevention in PTSD patients.
The most significant PTSD feature is development of
specific psychopatological symptoms, as response to the
stressor event, or any other situation of extremely threa-
tening or chatastrofic nature. The stressor experience
that occurs prior to PTSD development, might be the
consequence of both witnessing and/or participating in
the traumatic events, such as war-related crimes, tor-
ture, terorism, rape, criminal act, severe traffic acci-
dents, etc. PTSD presents itself with the involuntary re-
-experience of the stressor event, where patient is conse-
quently avoiding all the reminders of the trauma, while
suffering from the numerous symptoms, such as: anxiety,
sleep disorders, irritability, anger outbursts, difficulty
concentrating, depresive mood, difficulties with control-
ling agressive impulses, with the increased risk of auto-
destructive and heterodestructive behaviour2–4.
PTSD is multisystemic disorder that is clinicaly mani-
fested both on psychological and somatic level. It is con-
sequence of the complex interrelationship and interac-
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tions of the biological and psychological predispositions,
as well as premorbidity of the personality on one side,
with the exposure to the psichological and sociocultural
factors, such as stress type and intensity, attitude of the
community towards the traumatized person, on the other
side5,6. All the research until now, have underlined the
fact that hypothalamus, amygdaloid nuclei, as well as
frontal and orbitofrontal cortex, play significant role in
the patophysiology of PTSD7,8. In the PTSD patients,
most authors have found low levels of urine cortisol, with
the unchanged or reduced plazma cortisol levels, which pre-
sents neuroendocrinological paradox by itself9,10. Such
findings in the PTSD patients are explained with the
chronic adaptation of the hypotalamic-pituitary-adrenal
axis to the stress situation10,11. Involvement of this sys-
tem in the suicidal behavioural biology, as well as the in-
teraction to the other neurotransmitter systems, have
not been sufficiently clarified until now12.
Patophysiologically, serotonine is related to the PTSD
symptoms, as it is considered that serotonine controls
symptoms such as hyperarrousal, increased impulsivity
and aggression, as well as sleep disturbance and mood
disorders13. Blood platelets are considered as periferal se-
rotonergic markers, since platelets share both structural
similarities with the serotonin neurons (similarities in
the serotonine uptake, storage and release), as well as
binding characteristics between serotonin and 5-HT2 re-
ceptors. Studies that have researched concentration of
the platelet serotonin concentration as well as platelet
MAO, in the patients with PTSD, have presented various
results, from the values that have not changed, to the
values that have been either increased or dicreased14–17.
Prevalence of the PTSD in the general population is
less than 1%18. Prevalence of the PTSD in the high risk
groups (i.e. war veterans, volcanic eruption victims and
crime victims) is considered to be from 3 to 58%18,19.
Suicidal behaviour is the ultimate way of desctructive
and agressive behaviour in the patients with PTSD.
While PTSD is associated with a high suicide rate, sui-
cidal behaviour often remains unrecognized and unrea-
chable to preventive measures, due to the overall comple-
xity of the clinical features20. In the research of sero-
tonergic system in patients with suicidal behaviour, nu-
merous findings presented disrupted neurotransmitter
systems11,17. Reduced liquor concentration of 5-HIAA
(5-hydroxyindoleacetic acid) is known as the most impor-
tant biological marker to predict the risk of suicidal
behaviour22. The research has shown the reduced values
of liquor 5-HIAA, in the group of PTSD patients with the
suicidal behaviour. The role of cortisol in the suicide etiol-




The study included 46 subjects diagnosed with PTSD
and attempted suicide, 41 subject diagnosed with PTSD
without attempted suicide and 50 phenotipically healthy
patients. The patients diagnosed with PTSD, were diag-
nosed using the diagnostic criteria of the ICD-10 (Inter-
national Classification of Mental and Behavioural Disor-
ders ICD-10; Clinical descriptions and diagnostic guide-
lines, 10th revision) and Diagnostic and Statistical Man-
ual of Mental Disorders (DSM-IV)18,24, produced by the
American Psychiatric Association, 4th revision. Patients
were not diagnosed with any other mental disorder, ac-
cording to the criteria of the above mentioned classifica-
tions. The suicide attempt has been diagnosed in accor-
dance to the ICD-10, classified by the Beck classification
of suicidal behaviour25.
Methods
Blood samples have been taken on the second day of
hospitalisation, in the »Sveti Ivan« Psychiatric Hospital,
on an empty stomack, during the usual laboratory evalu-
ation, according to the standardized procedure, in accor-
dance with the ethics principles (with the approval of the
Ethics Committee of the Hospital and with the Informed
Consent of the patient). Blood samples of the phenoty-
pically healthy patients, have been taken in the Croatian
Institute for Transfusion Medicine, and delivered to the
Medical Biochemical Laboratory of the »Sveti Ivan« Psy-
chiatric Hospital, to be analysed, with the written con-
sent of the voluntary blood donor.
Platelet serotonin concentration was determined by
the competitive enzyme immunoassay (enzyme-linked
immunosorbent assay test-ELISA test, produced by Bio-
Source, Belgium), on immunoanalyser Elysis Uno (Hu-
man, Germany), while the serum cortisol level concen-
tration, has been determined by the enzyme immuno-
assay test, produced by Human, Germany, on Elysis Uno
immunoanalyser.
All conclusions have been reached upon conduct of
statistical tests and results have been interpreted at 5%
significance level. The statistical evaluation of the data
have applied descriptive statistics methods, t-test, ANOVA
test, Mann-Whitney U, Kruskal-Wallis test, ROC (Re-
ceiver operating characteristic) curve. Statistical Pack-
age for Social Sciences Software (SPSS) 13.0 for Windows
has been used for all of the above statistical evaluation.
Results
Therapy has been provided to both groups of PTSD
patients, with and without suicidal behaviour. Propor-
tion and quantitative share of specific medicaments have
been presented for both groups. The application of the
Fisher’s exact test has shown no difference among the
groups, with regards to the proportion of the particular
medicament (Table 1) Odds ratio (OR) for the suicide
attempt, with regards to the SSRI therapy (antidepres-
sants from the group of selective serotonin reuptake in-
hibitors), was not statistically significant at 5% significance
level (OR= 0.459; 95 % CI=0.191–1.104; p=0.082).
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Upon testing the normality of distribution with Kol-
mogorov-Smirnov test (K-S test), where the result has
shown normal Gauss distribution curve (p=0.269) of the
serum cortisol concentration, the ANalysis Of VAriance
(or ANOVA) has presented no statistically significant dif-
ference in the cortisol concentration accross all of the pa-
tient groups (F=2.578; df=2; p=0.080). For the group of
patients that have been taking SSRI therapy, equal vari-
ance T-test (test for homogeneity of variance)has shown
no statistically significant difference in the average cor-
tisol concentration (t=–0.488; df=31; p=0.629), among
the group of PTSD patients with and without suicide
attempt. In the presented group of patients with PTSD
and attempted suicide, there was only one male patient
included in the group, the results of the statistical analy-
sis are related to the female patients only.
Upon testing the normality of distribution with Kol-
mogorov-Smirnov test (K-S test), it was shown that the
platelet serotonin concentration of female patients does
not differ from the normal (Gauss) distribution curve
(p=0.098), in the way that would present statistically
significant difference. The analysis of the variance has
shown that within the group of female patients, there
was statistically significant difference of the average
platelet serotonin concentration among the groups (F=
9.152; df=2; p=0.001). Tamhane-T2 post hoc test for
inhomogeneous variances were applied for comparisons
among the groups. It was shown that female PTSD pa-
tients without attempted suicide, have statistically signi-
ficant decrease of the average platelet serotonine concen-
tration, compared to the female PTSD patients with
attempted suicide (F= 9.152; df=2; p=0.001), as well as
compared to the helthy female population (p<0.001). Va-
lues of the average platelet serotonin concentration in the
groups of female patients, have been shown in the Table 2.
T-test for inhomogeneous variances applied to the
group of patients taking SSRIs (selective serotonin reup-
take inhibitors) has shown no statistically significant dif-
ference of the average platelet serotonine concentration,
amongst suicidal PTSD patients and nonsuicidal PTSD
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TABLE 1
MEDICATION ADMINISTERED TO PATIENTS PRESENTING WITH PTSD
Therapy
PTSD with attempted suicide PTSD without attempted suicide Total p*
N (%) N (%) N (%)
SSRIs No 32 (69.6) 21 (51.2) 53 (60.9)
0.123Yes 14 (30.4) 20 (48.8) 34 (39.1)
Total 46 (100.0) 41 (100.0) 87 (100.0)
New No 43 (93.5) 34 (82.9) 77 (88.5)
0.180Antipsychotics Yes 3 (6.5) 7 (17.1) 10 (11.5)
Total 46 (100.0) 41 (100.0) 87 (100.0)
Classical
Antipsychotics
No 42 (91.3) 33 (80.5) 75 (86.2)
0.214Yes 4 (8.7) 8 (19.5) 12 (13.8)
Total 46 (100.0) 41 (100.0) 87 (100.0)
Anxiolytics No 20 (43.5) 18 (43.9) 38 (43.7)
>0.999Yes 26 (56.5) 23 (56.1) 49 (56.3)
Total 46 (100.0) 41 (100.0) 87 (100.0)
Hypnotics No 39 (84.8) 29 (70.7) 68 (78.2)
0.128Yes 7 (15.2) 12 (29.3) 19 (21.8)
Total 46 (100.0) 41 (100.0) 87 (100.0)
Other medicaments No 36 (78.3) 32 (78.0) 68 (78.2)
>0.999Yes 10 (21.7) 9 (22.0) 19 (21.8)
Total 46 (100.0) 41 (100.0) 87 (100.0)
TABLE 2
PLATELET SEROTONIN CONCENTRATION (ng/109 PLATELETS) IN FEMALE PATIENT GROUPS
Patient Group X SD (+/–) Median Q1–Q3 N
PTSD with attempted suicide 787.77 675.02 527.03 263.16–1223.98 17
PTSD without attempted suicide 182.60 147.09 172.21 66.00–241.84 13
Healthy Control Group 1105.26 660.90 880.36 497.61–1721.74 14
Total 709.99 667.07 470.67 175.82–910.88 44
patients (t=–1.746; df=3; p=0.178). Although there is
obvious big difference of the average platelet serotonine
concentration, this is not statistically significant for two
reasons: small number of patients in one of the groups
and inhomogeneous variance of the groups. Results are
presented in Table 3.
ANOVA test and SNK post hoc test (N=44, F=8.966,
p<0.001), presented the difference in the platelet seroto-
nin concentration accross all the groups of female pa-
tients, while the nonsuicidal PTSD female patients with
SSRI therapy, have shown statistically significant reduc-
tion of the platelet serotonine concentration, compared
to the nonsuicidal PTSD female patients with no SSRI
therapy (152 ng/109 platelets vs. 216 ng/109 platelets).
The same analysis has been shown statistically lower
platelet serotonin concentration in the group of the sui-
cidal PTSD patients with SSRIs therapy, compared to the
group of PTSD patients without SSRI therapy (716 ng/
109 platelets vs. 891 ng/109 platelets).
ROC analysis has been used in order to evaluate diag-
nostic accuracy of the platelet serotonin concentration in
the group of PTSD patients with and without attempted
suicide, compared to the phenotypically healthy control
group. Out of 44 patients analysed, with the cut-off
platelet serotonine concentration of 594.43 (ng/109 plate-
lets), optimizing specificitiy/sensibility pair, the value of
the area under the ROC curve was 79% (p=0.002), with
test specificity of 71.4%, which means that 71.4% women
from the group of healthy controls, have platelet seroto-
nine concentration greater then or equal to 594.43 ng/109
platelets and test sensitivity of 73.3%, which means that
73.3% women from group of PTSD patients, have the
platelet serotonin concentration less then or equal to
594.43 (ng/109 platelets). Results are shown in the Table
4. Positive predictive value (PPV) of the platelet seroto-
nin concentration is 84.6%, meaning that 84.6% of wo-
men, with the platelet serotonine concentration less then
or equal to 594.43 ng/109platelets, do belong to the group
of PTSD patients. Negative predictive value (NPV) of the
platelet serotonin concentration is 55.7%, meaning that
55.7% of women with the platelet serotonine concentra-
tion greater then or equal to 594.43 ng/109 platelets, be-
longs to the group of healthy controls.
Discriminatory efficacy of the platelet serotonin con-
centration has been tested, in order to determine belong-
ing to the group of women with PTSD and attempted sui-
cide, in relation to the group of women with PTSD
without attempted suicide. The value of the area under
the curve was 82% (p=0.003), with the cut-off platelet
serotonine concentration of 303.12 (ng/109 platelets).
The sensitivity of platelet serotonin concentration
used as diagnostic test is 76.5%, which means that 76.5%
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TABLE 4
ROC ANALYSES RESULTS IN THE GROUP OF FEMALE PTSD PATIENTS (PTSD WITH/WITHOUT ATTEMPTED SUICIDE) IN RELATION
TO THE PHENOTYPICALLY HEALTHY CONTROL GROUP
Healthy control group
PTSD with and without
attempted suicide
Total
N (%) N (%) N (%)
Platelet serotonine
concentration
594.43 ng/109 platelet 10 (71.4) 8 (26.7) 18 (40.9)
594.43 ng/109 platelet 4 (28.6) 22 (73.3) 26 (59.1)
Total 14 (100.0) 30 (100.0) 44 (100.0)
TABLE 3
PLATELET SEROTONIN CONCENTRATION (ng/109 PLATELET) RELATED TO SSRIs IN PTSD PATIENT GROUPS
Analit Group X SD (+/–) Median Q1–Q3 N
Platelet serotonin
concentration
PTSD without attempted suicide 152.53 102.81 130.43 96.15–226.93 15
PTSD with attempted suicide 716.01 643.36 621.29 149.50–1377.23 4
TABLE 5
ROC ANALYSES RESULTS IN THE GROUP OF FEMALE PTSD PATIENTS WITH ATTEMPTED SUICIDE IN RELATION TO THE GROUP OF
FEMALE PTSD PATIENTS WITHOUT ATTEMPTED SUICIDE
PTSD without attempted suicide PTSD with attempted suicide Total
N (%) N (%) N (%)
Platelet serotonin
concentration
303.12 ng/109 platelets 11 (84.6) 4 (23.5) 15 (50.0)
303.12 ng/109 platelets 2 (15.4) 13 (76.5) 15 (50.0)
Total 13 (100) 17 (100) 30 (100)
of women from the group of PTSD patients with attem-
pted suicide, have the platelet serotonin concentration
greater then or equal to 303.12 ng/109 platelets.
The specificity of platelet serotonin concentration used
as diagnostic test is 84.6%, which means that 84.6% of
women from the group of PTSD patients without attemp-
ted suicide, have the platelet serotonin concentration
lesser then or equal to 303.12 ng/109 platelets.
Positive predictive value of the platelet serotonin con-
centration (PPV) is 86.7%, meaning that 86.7% of wo-
men, with the platelet serotonine concentration greater
then or equal to 303.12 ng/109 platelets, do belong to the
group of PTSD patients with attempted suicide.
Negative predictive value of the platelet serotonin
concentration (NPV) is 73.3%, meaning that 73.3% of
women, with the platelet serotonine concentration lesser
then 303.12 ng/109 platelets, do belong to the group of
PTSD patients without attempted suicide.
Discussion
Suicidal behaviour often remains unrecognised and
remains outside of prevention measures, due to teh com-
plexity of the PTSD clinical presentation. Research of
both the risk of suicide and the exposure to the traumatic
event, with and without subsequent PTSD, it has been
established that PTSD is clearly related to the increased
risk of suicide and that PTSD is independent predictor of
the suicidal risk26,27. Numerous biological studies have
been conducted in order to identify the biological sup-
strate of suicidality. Suicidal behaviour is believed to in-
volve alterations in different neurotransmitter systems,
and most extensive evidence of the neurotransmitter
disfunction have been obtained from the serotonergic
system research17. Studies that have been researching
suicide and serotonergic neurotransmitter system, have
unonimously documented that decreased level of 5-HIAA
(5-hydroxyindoleacetic acid – key metabolic substance in
the serotonic decomposition) in liquor together with the
previous attempt of suicide, may be considered as suicide
predictors28. According to the results of this research,
platelet serotonin concentration is statistically signifi-
cantly lower in the group of PTSD patients without sui-
cide attempt (182.60 ng/109 platelets) and with suicide
attempt (787.77 ng/109 platelets), when compared to the
group of phenotipically healthy controls (1105.26 ng/109
platelets).
Number of studies have delt with the possibility of in-
creased suicidal risk during antidepressive therapy, in-
cluding SSRIs, especially within the group of children
and adolescents29. In this resaserch, odds ratio (OR) for
the suicide risk in the group of patients on SSRIs, is not
considered to be statistically significant at 5% signifi-
cance level (OR=0.459, 95% CI=0.191–1.104, p=0.082).
In relation to decreased platelet serotonin concentra-
tion in the group of PTSD patients without attempted
sucide (182.60 ng/109 platelets), compared to the group of
PTSD patients with attempted suicide (787.77 ng/109
platelets), as well as the fact that 68% of patients have
been on therapy, possible impact of SSRIs therapy to the
platelet serotonin concentration has been researched.
PTSD patients with and without attempted suicide, have
been analysed according to SSRIs intake. ANOVA test
and SNK post hoc test, presented reduced platelet seroto-
nin concentration in the group that has received SSRIs,
both in the group of PTSD patients with and without sui-
cide attempt.
When taking antidepressant therapy from the SSRI
group (39% patients have been taking SSRIs), there was
no statisticaly significant difference amongst the groups
(Fisher exact test p=0.123). The same was observed with
other kinds of therapy (anxiolytics and hypnotics), there
was no statisticaly significant difference amongst the pa-
tient groups (p>0.05). All of the presented data, both
from the literature, as well as results obtained through
our research, we may conclude that response to the anti-
depressant therapy was better in the group of the PTSD
patients with the suicide attempt.
In order to evaluate platelets serotonin concentration
diagnostic accuracy, ROC analysis has been used in fe-
male PTSD patient groups, with and without suicide at-
tempt (as there was no difference in the proportions re-
lated to the use of medicaments), compared to the group
of the phenotipically healthy controls. Platelet serotonin
concentration discriminatory efficacy has been examined
as well, in order to distinguish female PTSD patients
with attempted suicide, from female PTSD patients
without attempted suicide. ROC analysis have shown
very high diagnostic reliability. According to the obtained
results, it is possible that platelet serotonin concentra-
tion is potential marker of the suicidal behaviour in the
patients with PTSD. For potential marker values, it
would be possible to use two discriminatory platelet sero-
tonin concentrations: 1. Platelet serotonin concentration
<594 ng/109 platelets, with 73% sensitivity, showing cha-
racteristics of the PTSD patient group with and without
suicide (marker of the possible suicidal risk) and i 2. Se-
rotonin concentration >303 ng/109 platelets with 77%
sensitivity, showing characteristics of teh PTSD patient
group with suicide attempt (marker of the probable sui-
cide risk). Platelet serotonin concentration in the range
from 303 to 594 ng/109 platelets, may serve as the suicide
risk predictors.
However, the limitation of this research is the fact
that basic platelet serotonin concentrations were not
known. This is the reason we can not say if the reduction
is related to the efficacy of the antidepressants, and/or it
is included within the pathophysiology of the serotonin
neurotransmission. In addition, only female patients with
PTSD have participated in the research of the platelet se-
rotonin concentration. Further research is needed, on
the larger patient pool, in order to clarify the gender im-
pact on the platelet serotonin concentration.
Prospective biological studies point out that disfun-
ction of HPA axis has predictive values for suicide20. In
this research, the conducted ANOVA variance analysis
has shown lack of statistically significant difference in
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the cortisol concentration, accross all patient groups
(F=2.578; df=2; p=0.080). The above mentioned results
are confirming HPA axis chronic dysfunctionality, where
even at the point of the acute stressor exposure (the at-
tempt of suicide), cortisol concentration remains un-
changed. Such findings are corresponding to the cortisol
level findings presented in former research. Accordingly,
the results achieved through ANOVA test, present no
statistically significant difference in the cortisol concen-
tration, across all patient groups (N=83; F=0,069; p=
0,976), distributed in accordance to SSRI therapy.
Platelet serotonin concentration values presented in
this research, have confirmed our basic hypothesis about
serotonin as the suicidal risk factor. Together with all
other clinical indicators, especially with attempt of sui-
cide, it can have predictive value in determining high
risk group for the attempt of suicide, within the group of
PTSD patients. The results presenting cortisol concen-
tration, present confirmation of the chronic disfun-
cionality of the HPA axis, as found in previous studies,
but can not be considered as the predictors for the risk of
suicide.
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SEROTONIN I KORTIZOL KAO SUICIDOGENI FAKTORI KOD OBOLJELIH OD PTSP-A
S A @ E T A K
Posttraumatski stresni poreme}aj ~esto se javlja u komorbiditetu s razli~itim psihijatrijskim poreme}ajima, a pove-
zan je i sa suicidalnim pona{anjem. Serotoninski sustav, hipotalamo-hipofizno-adrenalni sustav i genetski ~imbenici u
skupini su biolo{kih faktora koji se istra`uju kao potencijalni biljezi koji bi op}enito mogli omogu}iti razlikovanje psi-
hi~ki oboljelih osoba sa suicidalnim pona{anjem, od psihi~ki oboljelih osoba bez suicidalnog pona{anja. U ovom radu
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ispitana je statisti~ka povezanost koncentracijâ serotonina u trombocitima i koncentracijâ kortizola u serumu i poku-
{aja suicida kod oboljelih od PTSP-a koji su lije~eni u PB »Sveti Ivan«. Glavna hipoteza je bila da postoje razlike u
perifernim biokemijskim pokazateljima u bolesnika s PTSP-om s poku{ajem suicida u odnosu na bolesnike s PTSP-om
bez poku{aja suicida, i u odnosu na fenotipski zdravu kontrolnu skupinu ispitanika. Utvr|ene su statisti~ki zna~ajno
sni`ene koncentracije serotonina u skupinama oboljelih od PTSP-a sa i bez poku{aja suicida u odnosu na fenotipski
zdravu skupinu, te da nema statisti~ki zna~ajne razlike u koncentraciji kortizola izme|u svih skupina. Rezultati su u
skladu s prethodnim istra`ivanjima te govore u prilog mogu}nosti da je koncentracija serotonina u trombocitima po-
tencijalni biljeg suicidalnog pona{anja u oboljelih od PTSP-a.
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